Clinical Trials DEA History Pharmaceutical 
Veriheal
JUNE 29, 2021
Plant medicines and concoctions made from them have been utilized throughout the history of cultures around the world. In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine.
Canna Law Blog
NOVEMBER 27, 2021
So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
AUGUST 11, 2021
MAPS Makes History. This will be the second clinical trial to give cannabis medicine or placebos to participating military veterans, and according to the Chief Science Officer of the MAPS Public Benefit Corporation, Berra Yazar-Klosinki, PhD, the first trial was a great success. “We
Cannabis Law Report
MARCH 2, 2020
This landmark approval is unique in that ketamine is well known to have hallucinogenic properties, as well as a long history as a party drug. Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA). The IPOs of Canopy Growth and GW Pharmaceuticals illustrate this point nicely.
Cannabis Law Report
JULY 9, 2021
Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link]. Drug Enforcement Agency (“DEA”).
Cannabis Law Report
FEBRUARY 28, 2022
Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Patents on psychedelics raise unique concerns associated with their unusual qualities, history, and regulation. Trial of Psilocybin Versus Escitalopram for Depression , 384 NEW ENG. Mitchell et al.,
SpeedWeed
MARCH 18, 2021
They also wrote: The study sample included participants with a history of cannabis use. Given the topical nature of the current trial and its relevance for public policy on medical cannabis, participants might have been biased to report positive effects regardless of condition. It tested at only 9% THC. Establishing cannabis as safe.
Expert insights. Personalized for you.
55 
Let's personalize your content